1. Home
  2. CRTO vs NVAX Comparison

CRTO vs NVAX Comparison

Compare CRTO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$20.01

Market Cap

1.1B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$6.83

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRTO
NVAX
Founded
2005
1987
Country
France
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2013
1995

Fundamental Metrics

Financial Performance
Metric
CRTO
NVAX
Price
$20.01
$6.83
Analyst Decision
Buy
Hold
Analyst Count
9
8
Target Price
$38.67
$9.75
AVG Volume (30 Days)
581.0K
3.2M
Earning Date
02-04-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
83.79
N/A
EPS
3.00
2.07
Revenue
$1,956,800,000.00
$1,064,651,000.00
Revenue This Year
N/A
$58.91
Revenue Next Year
$1.42
N/A
P/E Ratio
$6.70
$3.35
Revenue Growth
0.53
20.27
52 Week Low
$19.00
$5.01
52 Week High
$47.27
$11.55

Technical Indicators

Market Signals
Indicator
CRTO
NVAX
Relative Strength Index (RSI) 47.16 47.95
Support Level $19.41 $6.36
Resistance Level $20.51 $7.00
Average True Range (ATR) 0.82 0.22
MACD 0.01 0.07
Stochastic Oscillator 31.16 66.67

Price Performance

Historical Comparison
CRTO
NVAX

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: